Metabolic aspects and viability of heparin/CPDA-1-stored red cell concentrate as a by-product of a high-yield factor VIII production method.
As a by-product of a new high-yield method of production of freeze-dried factor VIII, red cell concentrate (RCC) containing a small amount of heparin besides CPDA-1 was studied. Compared to CPDA-1 stored RCC no difference was found in hematology parameters and 2,3-DPG levels during 28 days storage. Although still in the normal range for transfusion, ATP levels were significantly lower compared to CPDA-1-stored RCC after 30 days shelf life. A survival study with 51Cr-labelled red cells showed good recovery and normal red cell half-life. Rapid transfusion of heparin/CPDA-1 RCC in 6 volunteers did not have any effect on aPTT. Heparin could not be detected in posttransfusion plasma samples.
D019794:2,3-Diphosphoglycerate; D000225:Adenine; D000255:Adenosine Triphosphate / Q000097:blood; D001793:Blood Preservation; D001803:Blood Transfusion; D002470:Cell Survival; D002951:Citrates; D004163:Diphosphoglyceric Acids / Q000097:blood; D004912:Erythrocytes / Q000166:cytology / Q000378:metabolism; D005169:Factor VIII / Q000302:isolation & purification; D005947:Glucose; D006493:Heparin; D006801:Humans; D010314:Partial Thromboplastin Time; D010710:Phosphates
C034876:CPDA solutions; D002951:Citrates; D004163:Diphosphoglyceric Acids; D010710:Phosphates; D019794:2,3-Diphosphoglycerate; D000255:Adenosine Triphosphate; D005169:Factor VIII; D006493:Heparin; D005947:Glucose; D000225:Adenine